BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2a study (ADMIRAL) of STK-001 for the treatment of Dravet syndrome.
STK-001, a proprietary antisense oligonucleotide (ASO), has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome, a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures that usually begin within the first year of life. Dravet syndrome is classified as a developmental and epileptic encephalopathy resulting in developmental delay and cognitive impairment, in addition to seizure activity, that arise from the genetic mutation that causes the disease.
We are making excellent progress with our ongoing studies of STK-001 in the U.S. The high level of interest from the Dravet community underscores the urgent need for new treatment options that go beyond seizure control, said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. The ADMIRAL study complements our U.S.-based MONARCH study, enabling the evaluation of higher dose levels of STK-001 and representing an initial step in the expansion of our global clinical development efforts. Together, we anticipate that these studies will generate a comprehensive set of data that will inform our future development plans. We look forward to working with the U.K. Dravet community patients, families and healthcare providers to add to our understanding of the potential for STK-001 to be the first disease-modifying therapy for Dravet syndrome.
ADMIRAL is an open-label, multi-center, Phase 1/2a study designed to assess the safety and tolerability of multiple doses of up to 70mg of STK-001, as well as to characterize human pharmacokinetics. Secondary endpoints include change in seizure frequency and quality of life measures. The study is expected to enroll approximately 22 children and adolescents with Dravet syndrome across multiple clinical sites in the United Kingdom. Patient enrollment and dosing are expected to start in the second half of 2021.
Current treatments for Dravet syndrome help us manage seizures, but some of the most devastating effects of the disease such as developmental and intellectual disabilities are not addressed by current therapies, said Professor Helen Cross, Honorary Consultant in Paediatric Neurology at Great Ormond Street Hospital for Children NHS Foundation Trust. There is great hope that a new approach, such as STK-001, that targets the root cause of the disease, may address the seizures as well as the myriad of devastating comorbidities that have impacts on patients and their families. Im pleased to be helping lead the effort to bridge the treatment gap by conducting the first study of STK-001 in the U.K. as the lead investigator for the ADMIRAL study.
MONARCH Phase 1/2a Clinical Trial is Ongoing in the United States
Enrollment of children and adolescents in the first two single ascending dose (SAD) cohorts (10mg and 20mg) is complete and enrollment and dosing in the third (30mg) SAD cohort is underway. Dosing above 30mg in this study remains on partial clinical hold with the U.S. Food and Drug Administration (FDA). Preliminary safety and pharmacokinetic data from the SAD portion of the MONARCH study are expected in the second half of 2021.
In addition, enrollment and dosing in the multiple ascending dose (MAD) portion of the MONARCH study is underway at the 20mg dose level. Patients who participated in the MONARCH study are eligible to continue treatment in SWALLOWTAIL, an open label extension (OLE) study designed to evaluate the long-term safety and tolerability of repeat doses of STK-001. Enrollment and dosing in SWALLOWTAIL are underway.
About STK-001
STK-001 is an investigational new medicine for the treatment of Dravet syndrome and is being evaluated in a Phase 1/2a clinical trial. Stoke believes that STK-001, a proprietary antisense oligonucleotide (ASO), has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome. STK-001 is designed to up-regulate NaV1.1 protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both occurrence of seizures and significant non-seizure comorbidities. Stoke has generated preclinical data demonstrating proof-of-mechanism and proof-of-concept for STK-001. STK-001 has been granted orphan drug designation by the FDA as a potential new treatment for Dravet syndrome.
About the Phase 1/2a MONARCH Clinical Study (United States)
The MONARCH study is a Phase 1/2a open-label study of children and adolescents ages 2 to 18 who have an established diagnosis of Dravet syndrome and have evidence of a genetic mutation in the SCN1A gene. The primary objectives for the study are to assess the safety and tolerability of STK-001, as well as to characterize human pharmacokinetics. A secondary objective is to assess the effect as an adjunctive antiepileptic treatment with respect to the percentage change from baseline in convulsive seizure frequency over a 12-week treatment period. Stoke also intends to measure non-seizure aspects of the disease, such as quality of life, as secondary endpoints. Enrollment and dosing are ongoing in MONARCH and Stoke plans to enroll approximately 48 patients in the study across 20 sites in the United States.
Additional information about the MONARCH study can be found at https://www.monarchstudy.com/.
Patients who participated in the MONARCH study are eligible to continue treatment in SWALLOWTAIL, an open label extension (OLE) study designed to evaluate the long-term safety and tolerability of repeat doses of STK-001. Enrollment and dosing in SWALLOWTAIL are underway.
About the Phase 1/2a ADMIRAL Study (United Kingdom)
The ADMIRAL study is a Phase 1/2a open-label study of children and adolescents ages 2 to <18 who have an established diagnosis of Dravet syndrome and have evidence of a genetic mutation in the SCN1A gene. The primary objectives for the study are to assess the safety and tolerability of multiple doses of STK-001, as well as to characterize human pharmacokinetics. A secondary objective is to assess the effect of multiple doses of STK-001 as an adjunctive antiepileptic treatment with respect to the percentage change from baseline in convulsive seizure frequency over a 24-week treatment period. Stoke also intends to measure non-seizure aspects of the disease, such as overall clinical status and quality of life, as secondary endpoints. Stoke plans to enroll approximately 22 patients in the study across multiple sites in the United Kingdom.
About Dravet Syndrome
Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures, beginning within the first year of life. Dravet syndrome is difficult to treat and has a poor long-term prognosis. Complications of the disease often contribute to a poor quality of life for patients and their caregivers. The effects of the disease go beyond seizures and often include severe intellectual disabilities, severe developmental disabilities, motor impairment, speech impairment, autism, behavioral difficulties and sleep abnormalities. The disease is classified as a developmental and epileptic encephalopathy due to the developmental delays and cognitive impairment associated with the disease. Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP. Approximately 85% of those diagnosed with Dravet syndrome have a mutation of the SCN1A gene. Dravet syndrome affects approximately 35,000 people in the United States, Canada, Japan, Germany, France and the United Kingdom, and it is not concentrated in a particular geographic area or ethnic group.
About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. Using the companys proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The companys first compound, STK-001 is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. The company is pursuing treatment for a second haploinsufficient disease, autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stokes initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting the companys belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow the company on Twitter at @StokeTx.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: enrollment in the ADMIRAL study and the studys ability to support our clinical development plans; our expectation about timing and execution of anticipated milestones; our ability to use ADMIRAL or MONARCH study data to advance the development of STK-001; the ability of STK-001 to treat the underlying causes of Dravet syndrome and the expected benefits thereof; and the ability of TANGO to design medicines to increase protein production and the expected benefits thereof. These forward-looking statements may be accompanied by such words as aim, anticipate, believe, could, estimate, expect, forecast, goal, intend, may, might, plan, potential, possible, will, would, and other words and terms of similar meaning. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our ability to develop, obtain regulatory approval for and commercialize STK-001, any potential clinical candidate for OPA1 and future product candidates; the timing and results of preclinical studies and clinical trials; the risk that positive results in a clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities and activities in international jurisdictions; the risk that regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; failure to protect and enforce our intellectual property and other proprietary rights; risks associated with current and potential delays, work stoppages, or supply chain disruptions caused by the coronavirus pandemic; risks associated with current and potential future healthcare reforms; failure to comply with legal and regulatory requirements in the United States and abroad; and the other risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements.
- New gene offers hope for preventive medicine against fractures [Last Updated On: September 18th, 2012] [Originally Added On: September 18th, 2012]
- Colon Cancer Gene Database May Assist Research Efforts [Last Updated On: September 30th, 2012] [Originally Added On: September 30th, 2012]
- Researchers discover gene that causes deafness [Last Updated On: September 30th, 2012] [Originally Added On: September 30th, 2012]
- Gene Study Yields New Clues to Breast Cancer [Last Updated On: September 30th, 2012] [Originally Added On: September 30th, 2012]
- Gene key to chemotherapy efficacy [Last Updated On: September 30th, 2012] [Originally Added On: September 30th, 2012]
- Gene clues offer new hope for treating breast cancer [Last Updated On: September 30th, 2012] [Originally Added On: September 30th, 2012]
- Gene that causes deafness pinpointed [Last Updated On: October 1st, 2012] [Originally Added On: October 1st, 2012]
- Gene that causes a form of deafness discovered [Last Updated On: October 1st, 2012] [Originally Added On: October 1st, 2012]
- Novel gene associated with Usher syndrome identified [Last Updated On: October 2nd, 2012] [Originally Added On: October 2nd, 2012]
- Translational Regenerative Medicine: Market Prospects 2012-2022 [Last Updated On: October 2nd, 2012] [Originally Added On: October 2nd, 2012]
- Two-day test can spot gene diseases in newborns [Last Updated On: October 3rd, 2012] [Originally Added On: October 3rd, 2012]
- Fast Gene Screen May Help Sick Babies [Last Updated On: October 3rd, 2012] [Originally Added On: October 3rd, 2012]
- Gene therapies need new development models [Last Updated On: October 3rd, 2012] [Originally Added On: October 3rd, 2012]
- Rapid gene machines used to find cause of newborn illnesses [Last Updated On: October 3rd, 2012] [Originally Added On: October 3rd, 2012]
- Gene behind many spontaneous breast cancers identified [Last Updated On: October 3rd, 2012] [Originally Added On: October 3rd, 2012]
- Gene responsible for many spontaneous breast cancers identified [Last Updated On: October 3rd, 2012] [Originally Added On: October 3rd, 2012]
- Two-day test can spot gene diseases in newborns - Wed, 03 Oct 2012 PST [Last Updated On: October 3rd, 2012] [Originally Added On: October 3rd, 2012]
- Researchers Discover Gene Defect Linked to Deafness [Last Updated On: October 3rd, 2012] [Originally Added On: October 3rd, 2012]
- Gene diseases in newborns unveiled quicker [Last Updated On: October 4th, 2012] [Originally Added On: October 4th, 2012]
- Quicker gene test may help babies - Thu, 04 Oct 2012 PST [Last Updated On: October 4th, 2012] [Originally Added On: October 4th, 2012]
- Rapid gene-mapping test may diagnose disease in newborns [Last Updated On: October 5th, 2012] [Originally Added On: October 5th, 2012]
- 2-day test can spot gene diseases in newborns [Last Updated On: October 5th, 2012] [Originally Added On: October 5th, 2012]
- Gene diseases in newborns spotted with 2-day test [Last Updated On: October 5th, 2012] [Originally Added On: October 5th, 2012]
- Rare Gene Deletion Tied To Psychiatric Disease And Obesity [Last Updated On: October 10th, 2012] [Originally Added On: October 10th, 2012]
- Mount Sinai researchers discover gene signature that predicts prostate cancer survival [Last Updated On: October 10th, 2012] [Originally Added On: October 10th, 2012]
- Test Spots Newborn Gene Disease [Last Updated On: October 10th, 2012] [Originally Added On: October 10th, 2012]
- Gene signature predicts prostate cancer survival [Last Updated On: October 11th, 2012] [Originally Added On: October 11th, 2012]
- Researchers Discover Gene Signature that Predicts Prostate Cancer Survival [Last Updated On: October 11th, 2012] [Originally Added On: October 11th, 2012]
- Bioethics Panel Urges More Gene Privacy Protection [Last Updated On: October 11th, 2012] [Originally Added On: October 11th, 2012]
- High Levels of Blood-Based Protein Specific to Mesothelioma [Last Updated On: October 11th, 2012] [Originally Added On: October 11th, 2012]
- Gene clues to help tackle skin disease [Last Updated On: October 15th, 2012] [Originally Added On: October 15th, 2012]
- Additive effect of small gene variations can increase risk of autism spectrum disorders [Last Updated On: October 15th, 2012] [Originally Added On: October 15th, 2012]
- 2-gene test predicts which patients with heart failure respond best to beta-blocker drug [Last Updated On: October 16th, 2012] [Originally Added On: October 16th, 2012]
- Two-gene test predicts which patients with heart failure respond best to beta-blocker drug [Last Updated On: October 16th, 2012] [Originally Added On: October 16th, 2012]
- Gene Linked to Kidney Failure [Last Updated On: October 17th, 2012] [Originally Added On: October 17th, 2012]
- Nanoparticles seen as gene therapy advance [Last Updated On: October 17th, 2012] [Originally Added On: October 17th, 2012]
- Stem Cell Therapy for Sickle Cell Anemia - Video [Last Updated On: October 31st, 2012] [Originally Added On: October 31st, 2012]
- Sickle Cell Anemia: Stem Cell Gene Therapy - Donald Kohn - Video [Last Updated On: October 31st, 2012] [Originally Added On: October 31st, 2012]
- Finding A Cure For Cancer with Dr. Aaron Rapoport - Video [Last Updated On: October 31st, 2012] [Originally Added On: October 31st, 2012]
- First gene therapy to go on sale in Europe in 2013: company [Last Updated On: November 7th, 2012] [Originally Added On: November 7th, 2012]
- Nanomedicine: Infectious Diseases, Immunotherapy, Diagnostics, Antifibrotics, Toxicology And Gene Me - Video [Last Updated On: November 14th, 2012] [Originally Added On: November 14th, 2012]
- Stress gene linked to heart attack – Study [Last Updated On: December 20th, 2013] [Originally Added On: December 20th, 2013]
- Why not gift yourself with gene test this Christmas? [Last Updated On: December 20th, 2013] [Originally Added On: December 20th, 2013]
- "Stress gene" may raise heart attack risk in healthy people [Last Updated On: December 20th, 2013] [Originally Added On: December 20th, 2013]
- 'Stress Gene' Ups Heart Attack, Death Risk [Last Updated On: December 20th, 2013] [Originally Added On: December 20th, 2013]
- Common disorders: It's not the genes themselves, but how they are controlled [Last Updated On: December 20th, 2013] [Originally Added On: December 20th, 2013]
- What is a gene? - Genetics Home Reference [Last Updated On: December 20th, 2013] [Originally Added On: December 20th, 2013]
- Gene Medicine | Business Outline | About Us | TAKARA BIO INC. [Last Updated On: December 20th, 2013] [Originally Added On: December 20th, 2013]
- Gene Therapy Clinical Trials Worldwide [Last Updated On: December 20th, 2013] [Originally Added On: December 20th, 2013]
- Genentech - Official Site [Last Updated On: December 21st, 2013] [Originally Added On: December 21st, 2013]
- Gene Therapy - American Medical Association [Last Updated On: December 23rd, 2013] [Originally Added On: December 23rd, 2013]
- Researchers identify gene that influences the ability to remember faces [Last Updated On: December 24th, 2013] [Originally Added On: December 24th, 2013]
- Gene That Influences Bonding Also Found To Impact Facial Recognition [Last Updated On: December 24th, 2013] [Originally Added On: December 24th, 2013]
- Gene Therapy Method Targets Tumor Blood Vessels [Last Updated On: December 24th, 2013] [Originally Added On: December 24th, 2013]
- Latin Americans inherited diabetes gene risk from Neanderthals [Last Updated On: December 26th, 2013] [Originally Added On: December 26th, 2013]
- Gene that influences the ability to remember faces identified [Last Updated On: December 30th, 2013] [Originally Added On: December 30th, 2013]
- Study supports a causal role in narcolepsy for a common genetic variant [Last Updated On: January 2nd, 2014] [Originally Added On: January 2nd, 2014]
- Increasing Investments in Molecular Biology Research Drives the Market for DNA Gene Chips, According to a New Trend ... [Last Updated On: January 2nd, 2014] [Originally Added On: January 2nd, 2014]
- Loss of Function of a Single Gene Linked to Diabetes in Mice [Last Updated On: January 3rd, 2014] [Originally Added On: January 3rd, 2014]
- Gene Medicine and Health [Last Updated On: January 3rd, 2014] [Originally Added On: January 3rd, 2014]
- Gene Therapy - Nature [Last Updated On: January 5th, 2014] [Originally Added On: January 5th, 2014]
- KidsHealth for Parents - Gene Therapy and Children [Last Updated On: January 5th, 2014] [Originally Added On: January 5th, 2014]
- Gene Patent Case Fuels U.S. Court Test of Stem Cell Right [Last Updated On: January 6th, 2014] [Originally Added On: January 6th, 2014]
- Gene Mutation Increases Certain Health Risks For Blacks, Study Finds [Last Updated On: January 6th, 2014] [Originally Added On: January 6th, 2014]
- Single faulty gene causes major type 2 diabetes symptom in mice [Last Updated On: January 6th, 2014] [Originally Added On: January 6th, 2014]
- No 'brakes' -- Study finds mechanism for increased activity of oncogene in certain cancers [Last Updated On: January 6th, 2014] [Originally Added On: January 6th, 2014]
- AML score that combines genetic and epigenetic changes might help guide therapy [Last Updated On: January 9th, 2014] [Originally Added On: January 9th, 2014]
- Stem cell research identifies new gene targets in patients with Alzheimer's disease [Last Updated On: January 9th, 2014] [Originally Added On: January 9th, 2014]
- 14 new gene targets in Alzheimer’s identified [Last Updated On: January 10th, 2014] [Originally Added On: January 10th, 2014]
- Scientists uncover new target for brain cancer treatment [Last Updated On: January 11th, 2014] [Originally Added On: January 11th, 2014]
- Tweaking MRI to Track Creatine May Spot Heart Problems Earlier, Penn Medicine Study Suggests [Last Updated On: January 13th, 2014] [Originally Added On: January 13th, 2014]
- RSNA: Gene Variation Associated with Brain Atrophy in Mild Cognitive Impairment [Last Updated On: January 14th, 2014] [Originally Added On: January 14th, 2014]
- Keeping Stem Cells Pluripotent [Last Updated On: January 14th, 2014] [Originally Added On: January 14th, 2014]
- Gene variation associated with brain atrophy in mild cognitive impairment [Last Updated On: January 14th, 2014] [Originally Added On: January 14th, 2014]
- Genes: MedlinePlus Medical Encyclopedia - National Library of ... [Last Updated On: January 15th, 2014] [Originally Added On: January 15th, 2014]
- Gene Therapy May Restore Sight in People With Rare Blinding Disease [Last Updated On: January 16th, 2014] [Originally Added On: January 16th, 2014]
- Gene therapy treats blindness [Last Updated On: January 16th, 2014] [Originally Added On: January 16th, 2014]
- New Genetic Clue to Lupus Is Found [Last Updated On: January 17th, 2014] [Originally Added On: January 17th, 2014]
- New Gene Machine Could Mean More Accurate Diagnosis [Last Updated On: January 18th, 2014] [Originally Added On: January 18th, 2014]
- Same cell death pathway involved in three forms of blindness, study finds [Last Updated On: January 18th, 2014] [Originally Added On: January 18th, 2014]